|
|
|
|
|
|
|
|
press release
Health Canada approves LYNPARZA™ for the Treatment of Ovarian Cancer in Patients with BRCA-Mutations
MISSISSAUGA, ON, May 3, 2016
/CNW/ - AstraZeneca Canada announced today that Health Canada has
approved LYNPARZA™ (olaparib) capsules as a maintenance treatment for
patients with platinum-sensitive relapsed BRCA-mutated (germline
or somatic) high grade serous epithelial ovarian, fallopian tube or
primary peritoneal cancer. LYNPARZA is the first poly ADP-ribose
polymerase (PARP) inhibitor available in Canada,
and has been granted the Health Canada Notice of Compliance with
Conditions (NOC/c), based on promising evidence of clinical efficacy and
duration of response data.1
"Health Canada's approval of LYNPARZA is particularly significant for patients with advanced BRCA-mutated
ovarian cancer. Until now, there have been very limited options
available to this unique segment of women living with this disease,"
says Dr. Michael Fung Kee Fung,
Head, Division of Surgical Oncology, Ottawa Regional Cancer Centre and
Professor, Division of Obstetrics & Gynecology and Department of
Surgery, University of Ottawa. "The availability of this targeted treatment which works in the presence of BRCA
mutations represents a successful application of our growing
understanding of this disease. It gives us another way to battle this
devastating disease, with fewer side effects compared to existing
chemotherapies, which can often be debilitating for patients.".....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.